Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk – Combined Results from Two Screening Trials
- 13 July 2017
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 23 (14), 3628-3637
- https://doi.org/10.1158/1078-0432.ccr-15-2750
Abstract
Purpose: Women at familial/genetic ovarian cancer risk often undergo screening despite unproven efficacy. Research suggests each woman has her own CA125 baseline; significant increases above this level may identify cancers earlier than standard 6- to 12-monthly CA125 > 35 U/mL. Experimental Design: Data from prospective Cancer Genetics Network and Gynecologic Oncology Group trials, which screened 3,692 women (13,080 woman-screening years) with a strong breast/ovarian cancer family history or BRCA1/2 mutations, were combined to assess a novel screening strategy. Specifically, serum CA125 q3 months, evaluated using a risk of ovarian cancer algorithm (ROCA), detected significant increases above each subject's baseline, which triggered transvaginal ultrasound. Specificity and positive predictive value (PPV) were compared with levels derived from general population screening (specificity 90%, PPV 10%), and stage-at-detection was compared with historical high-risk controls. Results: Specificity for ultrasound referral was 92% versus 90% (P = 0.0001), and PPV was 4.6% versus 10% (P > 0.10). Eighteen of 19 malignant ovarian neoplasms [prevalent = 4, incident = 6, risk-reducing salpingo-oophorectomy (RRSO) = 9] were detected via screening or RRSO. Among incident cases (which best reflect long-term screening performance), three of six invasive cancers were early-stage (I/II; 50% vs. 10% historical BRCA1 controls; P = 0.016). Six of nine RRSO-related cases were stage I. ROCA flagged three of six (50%) incident cases before CA125 exceeded 35 U/mL. Eight of nine patients with stages 0/I/II ovarian cancer were alive at last follow-up (median 6 years). Conclusions: For screened women at familial/genetic ovarian cancer risk, ROCA q3 months had better early-stage sensitivity at high specificity, and low yet possibly acceptable PPV compared with CA125 > 35 U/mL q6/q12 months, warranting further larger cohort evaluation. Clin Cancer Res; 23(14); 3628–37. ©2017 AACR.Keywords
Other Versions
This publication has 45 references indexed in Scilit:
- Large Prospective Study of Ovarian Cancer Screening in High-Risk Women: CA125 Cut-Point Defined by Menopausal StatusCancer Prevention Research, 2011
- The Road from Discovery to Clinical Diagnostics: Lessons Learned from the First FDA-ClearedIn VitroDiagnostic Multivariate Index Assay of Proteomic BiomarkersCancer Epidemiology, Biomarkers & Prevention, 2010
- Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and MortalityJAMA, 2010
- A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic massGynecologic Oncology, 2009
- New Insights Into the Pathogenesis of Serous Ovarian Cancer and Its Clinical ImpactJournal of Clinical Oncology, 2008
- A Prospective Study of Risk-Reducing Salpingo-oophorectomy and Longitudinal CA-125 Screening among Women at Increased Genetic Risk of Ovarian Cancer: Design and Baseline Characteristics: A Gynecologic Oncology Group StudyCancer Epidemiology, Biomarkers & Prevention, 2008
- A parametric empirical Bayes method for cancer screening using longitudinal observations of a biomarkerBiostatistics, 2003
- Screening Based on the Risk of Cancer Calculation From Bayesian Hierarchical Changepoint and Mixture Models of Longitudinal MarkersJournal of the American Statistical Association, 2001
- Probability of Carrying a Mutation of Breast-Ovarian Cancer Gene BRCA1 Based on Family HistoryJNCI Journal of the National Cancer Institute, 1997
- Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging.BMJ, 1993